Preclinical efficacy & intermediate endpoint biomarkers IDIQ
Active Master IDIQ Awarded
- Federal agency
-
National Cancer Institute
- Awardees
- 6
- Task orders
- 5
- Obligated
- $5,018,340
Vehicle facts
- Opportunity
-
- Prevent IDIQ mato RFP Pre-Solicitation · 75N91023R00024 · Posted Dec 19, 2022
- Agency
-
- National Cancer Institute National Institutes of Health, Department of Health and Human Services
- Combined task order value
-
- $5,018,340 Current, with exercised options
- $6,737,170 Potential, with all options
- Last date to order 55% complete
- Shared ceiling 3% used
- $149,995,000.00
IDV award and task order details come from SAM.gov/FPDS.
About this vehicle
The National Cancer Institute awarded this Master IDIQ on January 25, 2024, with ordering authority running through January 24, 2029, to contract preclinical efficacy evaluation and intermediate endpoint biomarker identification for cancer preventive agents and vaccines under the PREVENT Cancer Preclinical Drug Development Program. The vehicle carries no set-aside restriction and operates as one of three parallel multiple-award IDIQ pools within PREVENT, alongside separate vehicles for CGMP manufacturing and toxicology/pharmacology testing.
The Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ encompasses evaluation of chemopreventive and immunopreventive regimens, identification of pharmacodynamic and efficacy biomarkers to support clinical trial advancement, and development support for multiple candidate cancer preventive agents. Task orders issued to date target specific agent candidates: mitochondria-targeted honokiol for lung cancer, erlotinib and mesalamine for colitis-associated colorectal cancer, time-restricted feeding for pancreatic cancer prevention, and mRNA vaccines for triple negative breast cancer.
The vehicle remains in early execution with modest activity. Four task orders have been awarded as of September 25, 2025, generating $5.6 million in combined potential value, of which $3.2 million (58%) is obligated. Annual ordering pace reached two task orders in both 2024 and 2025. The combined potential value of $149.995 million across the shared ceiling indicates substantial unexercised capacity.
Competition is concentrated among academic research institutions. University of Oklahoma holds two orders with $3.1 million combined potential value; The University of Texas M.D. Anderson Cancer Center holds the other two orders with $2.5 million combined potential value. All four orders are unrestricted, firm-fixed-price or cost-sharing task orders. Individual task-order values range from approximately $1.1 million to $1.9 million in ceiling amount. Ultimate completion dates span December 2026 through March 2028. The National Cancer Institute is the sole customer across all four orders.
Description
The overall objective of the current acquisition, designated as the PREVENT Cancer Preclinical Drug Development Program, is to provide a structured approach to drug and vaccine development, from discovery to the clinic
IDV awards
Latest task orders
Top awardees by obligations
| Rank | Awardee | Obligated | Share |
|---|---|---|---|
| 1 | University Of Oklahoma | $3,142,485 | 63% |
| 2 | The Univeristy Of Texas M.d. Anderson Cancer Center | $1,875,855 | 37% |
Top funding agencies by obligations
| Rank | Funding agency | Obligated | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $5,018,340 | 100% |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2026 | $1,775,973 |
| FY2025 | $1,925,757 |
| FY2024 | $1,316,610 |
Quick answers
What is the Preclinical efficacy & intermediate endpoint biomarkers IDIQ contract vehicle?
Preclinical efficacy & intermediate endpoint biomarkers IDIQ is an indefinite delivery, indefinite quantity (IDIQ) contract vehicle run by National Cancer Institute (National Institutes of Health), awarded on January 25, 2024.
Which companies hold Preclinical efficacy & intermediate endpoint biomarkers IDIQ?
6 companies hold Preclinical efficacy & intermediate endpoint biomarkers IDIQ's IDV awards, one each. The latest went to IIT Research Institute on January 25, 2024. The awardees whose task orders obligated the most are University Of Oklahoma and The Univeristy Of Texas M.d. Anderson Cancer Center.
How much has been spent through Preclinical efficacy & intermediate endpoint biomarkers IDIQ?
5 task orders have been placed under Preclinical efficacy & intermediate endpoint biomarkers IDIQ, obligating $5,018,340.
What is the shared ceiling of Preclinical efficacy & intermediate endpoint biomarkers IDIQ?
Preclinical efficacy & intermediate endpoint biomarkers IDIQ's shared ceiling is $149,995,000; its task orders have used 3% of it.
Which agencies use Preclinical efficacy & intermediate endpoint biomarkers IDIQ the most?
The departments whose task orders under Preclinical efficacy & intermediate endpoint biomarkers IDIQ obligated the most are Department of Health and Human Services ($5,018,340).
How much was obligated through Preclinical efficacy & intermediate endpoint biomarkers IDIQ in fiscal year 2025?
Task orders under Preclinical efficacy & intermediate endpoint biomarkers IDIQ obligated $1,925,757 in fiscal year 2025.
On GovTribe
See this vehicle's full record
- Every IDV award and task order
- Funding by agency, awardee, NAICS and set-aside
- Teaming partners on this vehicle
- Ask GovTribe AI about this vehicle